CareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company's commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. Its products under development for transplant monitoring include AlloSure, a development-stage transplant surveillance solution, which applies next generation sequencing to detect and quantitate genetic differences between donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in the blood stream emanating from the donor heart. It offers the AlloMap Score Variability service, which provides complementary information to help personalize long-term care of heart transplant recipients.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Diagnostics & Testing
- Sub-Industry: N/A
- Symbol: NASDAQ:CDNA
- CUSIP: N/A
- Web: www.caredxinc.com
Capitalization:- Market Cap: $27.85 million
- Outstanding Shares: 21,421,000
Average Prices:- 50 Day Moving Avg: $1.16
- 200 Day Moving Avg: $1.58
- 52 Week Range: $0.76 - $5.06
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.21
- P/E Growth: -0.08
Sales & Book Value:- Annual Revenue: $45.65 million
- Price / Sales: 0.55
- Book Value: $0.69 per share
- Price / Book: 1.70
Profitability:- EBIDTA: ($11,230,000.00)
- Net Margins: -77.02%
- Return on Equity: -69.67%
- Return on Assets: -20.13%
Debt:- Current Ratio: 0.44%
- Quick Ratio: 0.32%
Misc:- Average Volume: 315,189 shs.
- Beta: 0.69
- Short Ratio: 1.63
Frequently Asked Questions for CareDx (NASDAQ:CDNA)
What is CareDx's stock symbol?
CareDx trades on the NASDAQ under the ticker symbol "CDNA."
How were CareDx's earnings last quarter?
CareDx, Inc. (NASDAQ:CDNA) posted its quarterly earnings results on Wednesday, August, 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.01. The company had revenue of $10.70 million for the quarter, compared to the consensus estimate of $10.42 million. CareDx had a negative return on equity of 69.67% and a negative net margin of 77.02%. CareDx's revenue was up 50.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.27) earnings per share. View CareDx's Earnings History.
When will CareDx make its next earnings announcement?
What guidance has CareDx issued on next quarter's earnings?
CareDx updated its first quarter earnings guidance on Monday, May, 22nd. The company provided earnings per share (EPS) guidance of ($0.32-0.27) for the period, compared to the Thomson Reuters consensus EPS estimate of ($0.19). The company issued revenue guidance of $11.4-11.6 million, compared to the consensus revenue estimate of $11.22 million.
Who are some of CareDx's key competitors?
Some companies that are related to CareDx include XOMA Corporation (XOMA), Sunesis Pharmaceuticals (SNSS), IntelGenx Technologies Corp. (IGXT), Fibrocell Science (FCSC), Akari Therapeutics PLC (AKTX), OvaScience (OVAS), pSivida Corp. (PSDV), Juniper Pharmaceuticals (JNP), Bellerophon Therapeutics (BLPH), The Joint Corp. (JYNT), Regulus Therapeutics (RGLS), ContraFect Corporation (CFRX), Zosano Pharma Corporation (ZSAN), KemPharm (KMPH), Aevi Genomic Medicine (GNMX), SCYNEXIS (SCYX), ADMA Biologics (ADMA) and Ekso Bionics Holdings (EKSO).
Who are CareDx's key executives?
CareDx's management team includes the folowing people:
- Michael D. Goldberg, Independent Chairman of the Board
- Peter Maag Ph.D., President, Chief Executive Officer, Director
- Michael Bell, Chief Financial Officer
- Mitchell J. Nelles Ph.D., Chief Operating Officer
- John J. Sninsky Ph.D., Chief Scientific Officer
- Josh DeFonzo, Chief Commercial Officer
- Matthew J. Meyer, Chief Business Officer
- James P. Yee M.D., Ph.D., Chief Medical Officer
- George W. Bickerstaff III, Independent Director
- Fred E. Cohen Ph.D., M.D., Independent Director
Who bought CareDx stock? Who is buying CareDx stock?
How do I buy CareDx stock?
Shares of CareDx can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CareDx's stock price today?
One share of CareDx stock can currently be purchased for approximately $1.17.
MarketBeat Community Rating for CareDx (NASDAQ CDNA)MarketBeat's community ratings are surveys of what our community members think about CareDx and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for CareDx (NASDAQ:CDNA) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for CareDx (NASDAQ:CDNA)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 6/15/2016 | Piper Jaffray Companies | Reiterated Rating | Overweight | $6.00 | N/A |  |
| 6/14/2016 | Leerink Swann | Reiterated Rating | Buy | | N/A | |
| 6/14/2016 | Mizuho | Boost Price Target | Buy | $8.00 -> $12.00 | N/A | |
| 2/9/2016 | Janney Montgomery Scott | Initiated Coverage | Buy -> Buy | $12.00 | N/A | |
| 11/18/2015 | Craig Hallum | Boost Price Target | Buy | $10.00 -> $13.00 | N/A | |
| 9/28/2015 | Raymond James Financial, Inc. | Downgrade | Outperform -> Market Perform | | N/A | |
(Data available from 7/25/2015 forward)
Earnings History for CareDx (NASDAQ:CDNA)Earnings History by Quarter for CareDx (NASDAQ CDNA)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/8/2017 | | ($0.19) | | | | | N/A | |
| 11/9/2016 | Q3 2016 | ($0.25) | ($0.17) | $11.50 million | $12.48 million | View | Listen | |
| 8/10/2016 | Q216 | ($0.28) | ($0.29) | $10.42 million | $10.70 million | View | Listen | |
| 5/6/2016 | Q1 | ($0.31) | ($0.37) | $6.97 million | $6.60 million | View | N/A | |
| 3/24/2016 | Q415 | ($0.34) | ($0.40) | $7.44 million | $6.60 million | View | Listen | |
| 11/11/2015 | Q315 | ($0.25) | ($0.29) | $7.34 million | $7.15 million | View | Listen | |
| 8/10/2015 | Q215 | ($0.18) | ($0.27) | $7.28 million | $7.13 million | View | Listen | |
| 5/12/2015 | Q115 | ($0.17) | ($0.19) | $6.82 million | $7.22 million | View | Listen | |
| 11/10/2014 | Q314 | ($0.13) | $0.01 | $6.60 million | $6.65 million | View | N/A | |
| 8/27/2014 | Q2 14 | ($0.13) | ($0.09) | $6.18 million | $6.78 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for CareDx (NASDAQ:CDNA)Current Year EPS Consensus Estimate: $-0.89 EPS
Next Year EPS Consensus Estimate: $-0.53 EPS
Dividend History for CareDx (NASDAQ:CDNA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for CareDx (NASDAQ:CDNA)Insider Ownership Percentage: 5.40%
Institutional Ownership Percentage: 36.52%
Insider Trades by Quarter for CareDx (NASDAQ:CDNA)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/29/2017 | Neil Gagnon | Major Shareholder | Buy | 1,808 | $1.11 | $2,006.88 | |
| 6/23/2017 | Neil Gagnon | Major Shareholder | Buy | 63,120 | $1.10 | $69,432.00 | |
| 5/24/2017 | Neil Gagnon | Major Shareholder | Buy | 7,439 | $1.00 | $7,439.00 | |
| 5/23/2017 | Neil Gagnon | Major Shareholder | Buy | 6,836 | $1.04 | $7,109.44 | |
| 4/28/2017 | Neil Gagnon | Major Shareholder | Buy | 15,116 | $0.89 | $13,453.24 | |
| 3/16/2017 | Neil Gagnon | Major Shareholder | Buy | 123,160 | $1.83 | $225,382.80 | |
| 9/22/2016 | Neil Gagnon | Major Shareholder | Buy | 178,686 | $4.00 | $714,744.00 | |
| 4/14/2016 | Neil Gagnon | Major Shareholder | Buy | 93,240 | $4.02 | $374,824.80 | |
| 10/21/2015 | Neil Gagnon | major shareholder | Buy | 1,431 | $4.99 | $7,140.69 | |
| 10/20/2015 | Neil Gagnon | Major Shareholder | Buy | 1,347 | $4.92 | $6,627.24 | |
| 9/29/2015 | Neil Gagnon | major shareholder | Buy | 6,332 | $6.10 | $38,625.20 | |
| 9/4/2015 | Neil Gagnon | Major Shareholder | Buy | 69,383 | $6.95 | $482,211.85 | |
| 6/5/2015 | Neil Gagnon | Major Shareholder | Buy | 6,500 | $5.69 | $36,985.00 | |
| 6/1/2015 | Peter Maag | CEO | Buy | 2,000 | $4.84 | $9,680.00 | |
| 4/17/2015 | Neil Gagnon | Major Shareholder | Buy | 13,051 | $5.34 | $69,692.34 | |
| 3/20/2015 | Neil Gagnon | Major Shareholder | Buy | 6,324 | $6.35 | $40,157.40 | |
| 2/27/2015 | Neil Gagnon | Major Shareholder | Buy | 4,270 | $6.03 | $25,748.10 | |
| 2/6/2015 | Neil Gagnon | Major Shareholder | Buy | 4,586 | $7.20 | $33,019.20 | |
| 2/5/2015 | Neil Gagnon | Major Shareholder | Buy | 121,587 | $7.10 | $863,267.70 | |
| 2/4/2015 | Neil Gagnon | Major Shareholder | Buy | 31,991 | $7.00 | $223,937.00 | |
| 2/3/2015 | Neil Gagnon | Major Shareholder | Buy | 23,558 | $7.03 | $165,612.74 | |
| 2/2/2015 | Neil Gagnon | Major Shareholder | Buy | 3,620 | $7.05 | $25,521.00 | |
| 1/29/2015 | Neil Gagnon | Major Shareholder | Buy | 15,395 | $7.04 | $108,380.80 | |
| 1/27/2015 | Neil Gagnon | Major Shareholder | Buy | 84,720 | $7.00 | $593,040.00 | |
| 1/22/2015 | Neil Gagnon | Major Shareholder | Buy | 48,670 | $7.13 | $347,017.10 | |
| 1/20/2015 | Neil Gagnon | Major Shareholder | Buy | 16,192 | $6.66 | $107,838.72 | |
| 1/15/2015 | Neil Gagnon | Major Shareholder | Buy | 39,109 | $6.43 | $251,470.87 | |
| 1/14/2015 | Neil Gagnon | Major Shareholder | Buy | 122,319 | $7.07 | $864,795.33 | |
| 7/22/2014 | Ken Ludlum | CFO | Buy | 7,000 | $10.00 | $70,000.00 | |
| 7/22/2014 | Michael Goldberg | Director | Buy | 25,000 | $10.00 | $250,000.00 | |
| 7/22/2014 | Perkins Caufield & Bye Kleiner | Major Shareholder | Buy | 52,770 | $10.00 | $527,700.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for CareDx (NASDAQ:CDNA)
Latest Headlines for CareDx (NASDAQ:CDNA)
| Source: |
|
| Date | Headline |
|---|
 | $11.87 Million in Sales Expected for CareDx, Inc. (NASDAQ:CDNA) This Quarter
www.americanbankingnews.com - July 22 at 12:44 PM |
| Reviewing CareDx (CDNA) and Digiliti Money (DGLT)
www.americanbankingnews.com - July 21 at 12:06 AM |
| -$0.20 Earnings Per Share Expected for CareDx, Inc. (NASDAQ:CDNA) This Quarter
www.americanbankingnews.com - July 20 at 9:15 AM |
 | 100,000th AlloMap Result Provided to Heart Transplant Patients
finance.yahoo.com - July 13 at 6:03 PM |
 | Asset Acquisitions Accelerate in Healthcare Sector Boosting Potential Revenue Growth
www.bizjournals.com - July 11 at 6:05 PM |
| ETFs with exposure to CareDx, Inc. : July 10, 2017
finance.yahoo.com - July 10 at 5:01 PM |
| CareDx, Inc. (NASDAQ:CDNA) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - July 4 at 6:32 PM |
| CareDx Restructures and Defers Certain Obligations to March 2019
finance.yahoo.com - July 3 at 5:03 PM |
| ETFs with exposure to CareDx, Inc. : June 28, 2017
finance.yahoo.com - June 28 at 5:02 PM |
| Insider Buying: CareDx, Inc. (CDNA) Major Shareholder Purchases 63,120 Shares of Stock
www.americanbankingnews.com - June 27 at 1:20 PM |
| $11.86 Million in Sales Expected for CareDx, Inc. (CDNA) This Quarter
www.americanbankingnews.com - June 25 at 7:40 AM |
| Zacks: Analysts Anticipate CareDx, Inc. (CDNA) to Announce -$0.16 EPS
www.americanbankingnews.com - June 23 at 10:20 PM |
| ETFs with exposure to CareDx, Inc. : June 16, 2017
finance.yahoo.com - June 16 at 4:58 PM |
| Myriad Genetics (MYGN) versus CareDx (CDNA) Head to Head Contrast
www.americanbankingnews.com - June 14 at 8:20 PM |
| CareDx, Inc. :CDNA-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017
finance.yahoo.com - June 14 at 4:58 PM |
| CareDx, Inc. (CDNA) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - June 11 at 8:58 PM |
| CareDx Inc (CDNA) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - June 9 at 8:21 PM |
| CareDx Reports First Quarter 2017 Financial Results
finance.yahoo.com - June 9 at 4:49 PM |
| CareDx reports 1Q loss
finance.yahoo.com - June 9 at 4:49 PM |
| Zacks Investment Research Downgrades CareDx Inc (CDNA) to Hold
www.americanbankingnews.com - June 8 at 5:56 PM |
| CareDx (CDNA) & National Research (NRCIB) Head to Head Analysis
www.americanbankingnews.com - June 5 at 4:10 PM |
| $11.23 Million in Sales Expected for CareDx Inc (CDNA) This Quarter
www.americanbankingnews.com - June 1 at 10:08 AM |
| CareDx Activities at European Federation of Immunogenetics Congress
finance.yahoo.com - May 30 at 12:09 PM |
| CareDx Inc (CDNA) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 25 at 7:58 PM |
 | CareDx (CDNA) Receives Letter from Nasdaq Regarding Non-Compliance with Listing Rule
www.streetinsider.com - May 24 at 9:07 PM |
| Edited Transcript of CDNA earnings conference call or presentation 22-May-17 8:30pm GMT
finance.yahoo.com - May 23 at 4:13 PM |
| CareDx Inc (CDNA) Updates Q1 Earnings Guidance
www.americanbankingnews.com - May 22 at 5:10 PM |
| CareDx Reports Preliminary First Quarter 2017 Financial Results
finance.yahoo.com - May 22 at 4:07 PM |
| CareDx to Announce First Quarter 2017 Preliminary Financial Results on May 22, 2017
finance.yahoo.com - May 19 at 8:52 AM |
| Zacks Investment Research Upgrades CareDx Inc (CDNA) to "Hold"
www.americanbankingnews.com - May 16 at 6:26 PM |
| Short Interest in CareDx Inc (CDNA) Drops By 72.0%
www.americanbankingnews.com - May 14 at 9:14 AM |
| Zacks: Analysts Expect CareDx Inc (CDNA) Will Post Quarterly Sales of $11.01 Million
www.americanbankingnews.com - May 6 at 7:38 AM |
| -$0.22 EPS Expected for CareDx Inc (CDNA) This Quarter
www.americanbankingnews.com - May 4 at 11:40 PM |
| CareDx Achieves Significant Milestone Towards CMS Coverage for AlloSure
finance.yahoo.com - May 4 at 4:20 PM |
| CareDx Inc (CDNA) Major Shareholder Neil Gagnon Buys 15,116 Shares
www.americanbankingnews.com - May 4 at 12:36 AM |
| CareDx (CDNA) Receives Daily News Sentiment Score of 0.12
www.americanbankingnews.com - May 3 at 11:52 PM |
| Insider Buying: CareDx Inc (CDNA) Major Shareholder Buys 15,116 Shares of Stock
www.americanbankingnews.com - May 2 at 10:54 PM |
| ETFs with exposure to CareDx, Inc. : April 28, 2017
finance.yahoo.com - April 28 at 5:10 PM |
| CareDx to Present Key AlloSure Validation Data at ATC
finance.yahoo.com - April 28 at 5:10 PM |
| CareDx (CDNA) Earning Favorable News Coverage, Study Shows
www.americanbankingnews.com - April 27 at 7:22 PM |
| CareDx, Inc. :CDNA-US: Earnings Analysis: Q4, 2016 By the Numbers : April 27, 2017
finance.yahoo.com - April 27 at 4:38 PM |
| CareDx Inc (CDNA) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 24 at 6:10 PM |
| CareDx (CDNA) Earning Positive Media Coverage, Report Shows
www.americanbankingnews.com - April 23 at 2:57 PM |
| CareDx (CDNA) Names Michael Bell as New CFO
www.streetinsider.com - April 22 at 4:06 PM |
| CareDx Reports Fourth Quarter and Full Year 2016 Financial Results
finance.yahoo.com - April 21 at 9:18 PM |
| CareDx Announces Receipt of Expected Letter from Nasdaq
finance.yahoo.com - April 21 at 9:18 PM |
| CareDx Appoints Michael Bell as Chief Financial Officer
finance.yahoo.com - April 21 at 9:18 PM |
| CareDx reports 4Q loss
finance.yahoo.com - April 21 at 9:18 PM |
| CareDx (CDNA) Receiving Somewhat Positive Media Coverage, AlphaOne Reports
www.americanbankingnews.com - April 20 at 4:08 PM |
| CareDx (CDNA) Getting Somewhat Negative Press Coverage, Report Shows
www.americanbankingnews.com - April 17 at 2:14 PM |
CareDx (CDNA) Chart for Tuesday, July, 25, 2017
